Apimeds Pharmaceuticals US, Inc. Income Statement

Income Statement Dec2023 Dec2024
Revenue & cost
Revenue -0.04M-0.12M
Operating items
Research & Development 0.10M
Selling, General & Administrative 0.65M1.28M
Operating Expenses 0.75M1.28M
Operating Income -0.75M-1.28M
EBIT -0.75M-1.28M
Non-operating items
Interest & Investment Income 0.01M0.00M
Non Operating Income -0.03M-0.11M
Net income details
EBT -0.78M-1.39M
Profit After Tax -0.78M-1.39M
Income from Continuing Operations -0.78M-1.39M
Consolidated Net Income -0.78M-1.39M
Income towards Parent Company -0.78M-1.39M
Net Income towards Common Stockholders -0.78M-1.39M
Additional items
EPS (Basic) -0.17-0.18
EPS (Weighted Average and Diluted) -0.17-0.18
Shares Outstanding (Weighted Average) 7.90M7.90M
EBITDA -0.75M-1.28M
Interest Expenses 0.04M0.12M